Scancell Receives GTAC, MHRA Approval For SCIB1 Phase I Trial
Scancell said that SCIB1 is a new DNA ImmunoBody vaccine being developed using its patented ImmunoBody technology for the treatment of melanoma. In addition, Scancell’s US partner Ichor
BeOne Medicines is set to invest $300m in expanding its manufacturing and research operations at the Princeton West Innovation Campus in Hopewell, New Jersey, US.